Anakinra for myocarditis in juvenile idiopathic arthritis.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: published in the Cardiovascular Surgical Research Laboratories, Texas Heart Institute Country of Publication: United States NLM ID: 8214622 Publication Model: Print Cited Medium: Internet ISSN: 1526-6702 (Electronic) Linking ISSN: 07302347 NLM ISO Abbreviation: Tex Heart Inst J Subsets: MEDLINE
    • Publication Information:
      Original Publication: Houston, TX : published in the Cardiovascular Surgical Research Laboratories, Texas Heart Institute, c1982-
    • Subject Terms:
      Pregnancy Complications, Cardiovascular*; Arthritis, Juvenile/*complications ; Interleukin 1 Receptor Antagonist Protein/*therapeutic use ; Myocarditis/*drug therapy; Antirheumatic Agents/therapeutic use ; Arthritis, Juvenile/drug therapy ; Female ; Humans ; Myocarditis/etiology ; Pregnancy ; Young Adult
    • Abstract:
      A 20-year-old pregnant woman with a history of juvenile idiopathic arthritis presented with flu-like symptoms, systemic inflammation with myocarditis, and severe cardiomyopathy. Six weeks earlier, her chronic-arthritis therapy had been changed from anakinra, an interleukin-1β receptor antagonist, to etanercept. When she resumed taking anakinra, her condition improved dramatically, including a complete recovery of ventricular function. Myocarditis is a well-recognized complication of systemic vasculitides. This unusual case emphasizes the important pathophysiologic role of interleukin receptors in the successful treatment of myocarditis. We suggest that clinical cardiologists be aware of the therapeutic usefulness of biological agents such as anakinra in patients with rheumatic conditions.
    • References:
      Circulation. 2003 Jun 10;107(22):2793-8. (PMID: 12771005)
      Cardiovasc Drugs Ther. 2009 Apr;23(2):129-35. (PMID: 19005744)
      Clin Exp Rheumatol. 2011 Nov-Dec;29(6):1021-3. (PMID: 22153586)
      Circulation. 2008 May 20;117(20):2670-83. (PMID: 18474815)
      Circulation. 2001 Sep 18;104(12 Suppl 1):I308-I3. (PMID: 11568074)
      Pediatr Rheumatol Online J. 2012 Apr 10;10:8. (PMID: 22490470)
      Clin Immunol. 2008 Jan;126(1):13-30. (PMID: 17916445)
      Ann Rheum Dis. 2009 Nov;68(11):1794-5. (PMID: 19822718)
      Joint Bone Spine. 2011 Jan;78(1):100-1. (PMID: 21036649)
      Circulation. 2008 May 20;117(20):2662-9. (PMID: 18474811)
      Ann Rheum Dis. 2007 Mar;66(3):422-3. (PMID: 17179171)
      Am J Cardiol. 2010 May 15;105(10):1371-1377.e1. (PMID: 20451681)
      Circulation. 2004 Apr 6;109(13):1594-602. (PMID: 15023878)
      Eur Heart J. 2011 Nov;32(21):2616-25. (PMID: 21705357)
      Circulation. 1994 Jan;89(1):252-7. (PMID: 8281654)
      J Am Coll Cardiol. 1999 Jul;34(1):177-80. (PMID: 10400008)
      Circulation. 2003 Jul 1;107(25):3133-40. (PMID: 12796126)
      Pediatr Cardiol. 2011 Aug;32(6):862-3. (PMID: 21544583)
      Circulation. 2001 Feb 27;103(8):1044-7. (PMID: 11222463)
    • Contributed Indexing:
      Keywords: Anti-inflammatory agents/therapeutic use; antirheumatic agents/therapeutic use; arthritis, juvenile rheumatoid/complications/drug therapy; disease susceptibility; heart/drug effects; interferon-beta/therapeutic use; interleukin 1 receptor antagonist protein; myocarditis/diagnosis; treatment outcome; ventricular dysfunction, left/drug effects
    • Accession Number:
      0 (Antirheumatic Agents)
      0 (Interleukin 1 Receptor Antagonist Protein)
    • Publication Date:
      Date Created: 20140107 Date Completed: 20141014 Latest Revision: 20211021
    • Publication Date:
      20221213
    • Accession Number:
      PMC3853823
    • Accession Number:
      24391342